Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.090 | 0.680 | 0.590 |
Stocks | 99.910 | 99.910 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 19.702 | 21.195 |
Price to Book | 3.332 | 4.173 |
Price to Sales | 2.314 | 2.490 |
Price to Cash Flow | 18.352 | 17.334 |
Dividend Yield | 1.133 | 1.320 |
5 Years Earnings Growth | 14.724 | 13.721 |
Number of long holdings: 74
Number of short holdings: 8
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 5.58 | 607.73 | +0.15% | |
Eli Lilly | US5324571083 | 4.83 | 785.54 | -0.48% | |
Medincell | FR0004065605 | 4.48 | 18.10 | +0.11% | |
Merck&Co | US58933Y1055 | 3.34 | 102.80 | +1.16% | |
Novartis | CH0012005267 | 2.95 | 92.75 | +0.89% | |
Boston Scientific | US1011371077 | 2.93 | 90.61 | +0.44% | |
Becton Dickinson | US0758871091 | 2.82 | 222.45 | -0.80% | |
Vimian Group AB | SE0015961982 | 2.39 | 44.30 | +1.26% | |
Thermo Fisher Scientific | US8835561023 | 2.36 | 524.41 | +2.23% | |
Novo Nordisk B | DK0062498333 | 2.21 | 743.4 | -2.03% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pluvalca Disruptive Opportunities A | 122.24M | -6.14 | -14.96 | - | ||
Pluvalca France Small Caps A | 96.99M | -4.33 | -5.21 | 5.51 | ||
Pluvalca Initiatives PME A | 74.54M | -10.13 | -9.81 | 7.44 | ||
Pluvalca Allcaps A | 55.62M | -1.79 | -0.33 | 6.19 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review